This compound is primarily studied in research/clinical settings & may not be widely available as a regulated over-the-counter supplement. Information is provided for educational purposes only — not as a recommendation to use. See our Safety page.
SS-31 (Elamipretide)
Mitochondria-targeting peptide investigated clinically; the pivotal phase 3 MMPOWER-3 trial did not meet its primary endpoints in the overall PMM population.
Save how you reacted, what dose worked, what to watch for, or anything you want to remember later in your Notes tab.
An earlier short-course dose-escalation study reported improved exercise performance after 5 days; the larger phase 3 MMPOWER-3 trial did not confirm sustained benefit on primary endpoints.
MMPOWER-3 found no significant improvement in 6-minute walk test distance or fatigue scores with 40 mg/day subcutaneous elamipretide vs. placebo over 24 weeks in the overall PMM population (Class I evidence of no benefit on primary endpoints). A post-hoc subgroup analysis suggested possible benefit in patients with nuclear DNA variants. Elamipretide was well-tolerated.
Stacks containing SS-31 (Elamipretide)
Public community stacks that include this ingredient.
Mitochondria-oriented peptide grouping. SS-31 has clinical trials in specific mitochondrial diseases; MOTS-C is mostly preclinical.